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Background
• Triple-negative breast cancer (TNBC)
is an aggressive disease with limited
treatment options.1
• Immunotherapeutic strategies that
activate the innate immune system
against TNBCs can supplement
current treatments.
• The CD47-SIRPα pathway offers a
new avenue of research.
• CD47 is an inhibitory protein which
sends a “don’t eat me” signal to the
SIRPα receptor on macrophages.2
• CD47 is expressed on healthy
hemopoietic cells, but is overly
expressed on many cancer cells.2
• Previous studies from our lab also
found that targeting the overly-
expressed ganglioside GD2 on TNBC
cells activates antibody-dependent
cellular cytotoxicity (ADCC).3
• We investigated CD47 expression in
TNBC cell lines and whether CD47-
SIRPα blocking antibodies induces
phagocytosis of cancer cells.
Hypothesis
Blocking CD47-SIRPα interaction
induces phagocytosis of TNBC cells.
Additionally, the combination of anti-
GD2 antibody and blocking antibodies
may further enhance phagocytosis.
Methods
• CD47 expression in TNBC cell lines
was assessed by flow cytometry.
• M1 Macrophages were successfully 
generated from monocytes isolated 
from healthy donor-derived peripheral 
blood.
• Macrophages were co-cultured with
GFP- or RFP-expressing TNBC cells,
and treated with anti-CD47, anti-
SIRPα mAbs, and anti-GD2
dinutuximab (ch14.18), alone or in
combination.
• Phagocytosis was quantified by the
real-time live-cell imaging system,
IncuCyte.
• Phagocytosis was defined as a
reduction in the area of TNBC cell
fluorescence.
Results
1. TNBC cell lines strongly 
express CD47.
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Fig. 1 CD47 expression in three triple-negative breast cancer cell 
lines, measured by flow cytometry.  Red peaks indicate the 
unstained control, and blue peaks indicate cells stained with PE 
conjugated anti-CD47 antibody. All three cell lines tested displayed 
over 90% CD47 expression.
2. Anti-SIRPα blocking antibody 
significantly increased macrophage-
mediated phagocytosis. 
3. The anti-GD2 antibody, 
dinutuximab, can induce 
phagocytosis alone, but does not 
increase the effects in combination 
with anti-SIRPα antibody.
4. The optimal ratio of TNBC cells 
to macrophages plated is between 
2:1 and 1:1.
Conclusion
• High CD47 expression in in TNBC 
cell lines indicates that TNBC is a 
strong candidate for testing CD47-
SIRPα inhibition.
• anti-SIRPα blocking antibody, 
enhances macrophage-mediated 
phagocytosis of TNBC.
• Dinutuximab alone is also able to 
induce macrophage-mediated 
phagocytosis, even without specific 
CD47-SIRPα blockade.
• The failure of antibody combinations 
to further decrease cell numbers is 
likely due to high macrophage-
enhancing activity of individual 
antibodies.
• Due to unintentional cell death even 
without treatment, we optimized the 
ratio of TNBC cells to macrophages 
plated to between 2:1 and 1: for 
future experiments.
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Fig. 2 Change in green fluorescence area of GFP-tagged SUM159 
cells in co-culture with macrophages over two days, as quantified by 
IncuCyte live-cell imaging. Treatment with 50 μg/mL of anti-SIRPα
mAb leads to a greater decrease in green area, compared to 50 
μg/mL of anti-CD47 and 50 μg/mL of IgG control. 
Fig. 3 Green fluorescence area after two days (Fig. 2). Treatment 
with 50 μg/mL of anti-SIRPα, compared to 50 μg/mL of anti-CD47 
mAb and IgG control, showing significantly decreased fluorescence 
and increased phagocytosis.


































Fig. 6 Decrease in green fluorescence area after treating a 
SUM159 GFP and macrophage co-culture with 20 μg/mL of 
dinutuximab or a combination of 20 μg/mL dinutuximab and 75 
μg/mL anti-SIRPα. After two days, the dinutuximab treatment 
resulted in slightly more phagocytosis than the combination. 
Rituximab and IgG combinations are used as controls. 
Fig. 7 Green fluorescence area at 60 hours in the treatment above 
(Fig 2), including IgG and rituximab controls and 75 μg/mL of anti-
SIRPα alone. Dinutuximab and anti-SIRPα mAb both displayed 

































500K : 100K Macro to
MDA-MB-231
100K : 100K Macro to
MDA-MB-231
60K : 100K Macro to
MDA-MB-231
Fig. 8 Green fluorescence area in co-cultures with varying 
ratios of macrophages plated to 100K MDA-MB-231 GFP 
cells added, along with IgG. 60K and 100K macrophages 
plated led to the least amount of unintentional TNBC cell 
death, while 500K (plated according to established 
guidelines) led to very high levels of cell death even without 
treatment.
Fig. 5 Representative images of treatment with 50 μg/mL of anti-
SIRPα mAb (left) compared to 50 μg/mL of IgG control (right) 
after two days. Anti-SIRPα mAb shows significantly less 













Fig. 2 CD68 and CD80 expression measured by flow cytometry in 
macrophages cultured according to established protocol. Cultured 
macrophages highly express CD80 and CD68, confirming that the 





































































































































































Dinutux 20 µg/ml +
SIRPa 75 µg/ml
Dinutux 20 µg/ml + IgG
75 µg/ml
Ritux 20 µg/ml + IgG 75
µg/ml
Ritux 20 µg/ml + SIRPa
75 µg/ml
